News & Updates

Show Multimedia Only

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025 by

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

HCPs, patients willing to trade off OCS benefits to avoid side effects

12 Dec 2025 by

Both patients and healthcare professionals prefer treatment for asthma attacks that avoids the side effects of oral corticosteroids (OCS), and both are willing to trade off benefits, according to a study.

HCPs, patients willing to trade off OCS benefits to avoid side effects

12 Dec 2025

MMP-9 tied to faster lung function decline, COPD development

12 Dec 2025

An elevated matrix metalloproteinase-9 (MMP-9) appears to cause lung function decline and the development of chronic obstructive pulmonary disease (COPD), suggests a study.

MMP-9 tied to faster lung function decline, COPD development

12 Dec 2025

SARS-CoV-2 reinfection ups paediatric long COVID risk

12 Dec 2025 by

Findings from the retrospective RECOVER-EHR* study show an increased risk of post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID, in children and adolescents after a SARS-CoV-2 reinfection.

SARS-CoV-2 reinfection ups paediatric long COVID risk

12 Dec 2025

Doxycycline shows potential schizophrenia-lowering benefit

12 Dec 2025

Psychiatric patients exposed to doxycycline appear to have a reduced risk of schizophrenia, according to a study.

Doxycycline shows potential schizophrenia-lowering benefit

12 Dec 2025

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

12 Dec 2025 by

The novel glycoprotein IIb/IIIa inhibitor zalunfiban, administered at first medical contact in patients having ST-elevation myocardial infarction (STEMI), enhances patency of the infarct-related artery upon arrival in the catheterisation laboratory, in the phase III CeleBrate trial. It also improves 30-day cardiovascular (CV) outcomes, without increasing major bleeding.

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

12 Dec 2025

Sleep apnoea may pose increased Parkinson’s disease risk

11 Dec 2025 by

People with obstructive sleep apnoea seem predisposed to later development of Parkinson’s disease, but this risk can be mitigated by early treatment with continuous positive airway pressure, as reported in a study.

Sleep apnoea may pose increased Parkinson’s disease risk

11 Dec 2025

Continuous use of TNFi on the rise in pregnant women

11 Dec 2025

A trend toward increased continuous use of tumour necrosis factor inhibitors has been observed throughout gestation, which suggests growing confidence in the safety and effectiveness of this medication during pregnancy, reveals a study.

Continuous use of TNFi on the rise in pregnant women

11 Dec 2025

CVD tops disease burden, death cause worldwide

11 Dec 2025 by

The leading cause of disease burden and death across the globe is still cardiovascular disease (CVD), with low, low-middle, and middle sociodemographic index (SDI) regions carrying the heaviest burden, according to a study.

CVD tops disease burden, death cause worldwide

11 Dec 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Rifaximin does not improve survival in severe cirrhosis

Rifaximin does not improve survival in severe cirrhosis

HCPs, patients willing to trade off OCS benefits to avoid side effects

HCPs, patients willing to trade off OCS benefits to avoid side effects

MMP-9 tied to faster lung function decline, COPD development

MMP-9 tied to faster lung function decline, COPD development

SARS-CoV-2 reinfection ups paediatric long COVID risk

SARS-CoV-2 reinfection ups paediatric long COVID risk

Doxycycline shows potential schizophrenia-lowering benefit

Doxycycline shows potential schizophrenia-lowering benefit

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

Sleep apnoea may pose increased Parkinson’s disease risk

Sleep apnoea may pose increased Parkinson’s disease risk

Continuous use of TNFi on the rise in pregnant women

Continuous use of TNFi on the rise in pregnant women

CVD tops disease burden, death cause worldwide

CVD tops disease burden, death cause worldwide